Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at William Blair

William Blair began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report released on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating on the specialty pharmaceutical company’s stock. William Blair also issued estimates for Tenax Therapeutics’ Q3 2024 earnings at ($1.50) EPS, Q4 2024 earnings at ($1.35) EPS, FY2024 earnings at ($6.90) EPS, FY2025 earnings at ($8.33) EPS, FY2026 earnings at ($9.05) EPS and FY2027 earnings at ($9.63) EPS.

Separately, StockNews.com started coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They issued a sell rating for the company.

Tenax Therapeutics Stock Down 1.8 %

NASDAQ TENX opened at $3.28 on Monday. Tenax Therapeutics has a one year low of $2.77 and a one year high of $61.20. The business has a 50 day simple moving average of $3.73 and a 200 day simple moving average of $3.60.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping the consensus estimate of ($1.99) by $0.16. On average, equities analysts predict that Tenax Therapeutics will post -6.68 EPS for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.